Skip to content
CFPS Research Archives

CJC-1295/Ipamorelin Blend

Early human Growth Hormone 3 sources

CJC-1295 and Ipamorelin are frequently combined in research to synergistically stimulate the release of growth hormone. CJC-1295 acts as a growth hormone-releasing hormone (GHRH) analog to increase basal GH levels, while Ipamorelin is a growth hormone secretagogue that induces pulsatile release. Together, they are studied for their potential to enhance muscle growth, fat loss, recovery, and anti-aging effects without significantly elevating cortisol or prolactin.

01Dosing reference

Amount
100-300 mcg of each compound per dose
Frequency
1-2 times daily (often morning and before bed)
Cycle
8-12 weeks on, followed by 4 weeks off
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

Dual Receptor Activation

CJC-1295 binds to GHRH receptors on the anterior pituitary, while Ipamorelin binds to the ghrelin/growth hormone secretagogue receptor (GHSR).

02

Synergistic GH Release

The simultaneous activation of both pathways increases both the amplitude of growth hormone pulses and the overall basal levels of growth hormone.

03

Downstream IGF-1 Elevation

Elevated GH stimulates the liver to produce Insulin-like Growth Factor 1 (IGF-1), which promotes protein synthesis, lipolysis, and cellular repair.

03Human evidence

CJC-1295 increases GH and IGF-1 levels in healthy adults.

Clinical studies on CJC-1295 demonstrated dose-dependent increases in mean GH and IGF-1 levels in human subjects while maintaining natural pulsatility.

Ipamorelin stimulates GH release without significantly affecting cortisol or prolactin.

Human trials showed that Ipamorelin effectively induces GH secretion with a highly selective profile, avoiding the stress hormone spikes seen with other secretagogues.

04Preclinical evidence

Synergistic effect of GHRH and GHRP on growth hormone release.

Animal models indicate that combining a GHRH analog with a GHRP results in a greater-than-additive (synergistic) release of growth hormone.

Improved bone density and muscle mass.

Rodent studies using growth hormone secretagogues show enhanced bone mineral density and muscle hypertrophy over extended periods of administration.

05What is known vs. unknown

Reasonably established
  • The combination leverages two different pathways (GHRH and GHSR) for a synergistic increase in growth hormone.
  • Ipamorelin is considered one of the mildest and most selective GHRPs, avoiding significant spikes in cortisol and prolactin.
  • CJC-1295 (often used without DAC, also known as Mod GRF 1-29) provides a steady increase in basal GH levels.
  • The blend is frequently researched for its potential to improve sleep quality, accelerate recovery, and enhance fat metabolism.
Unknowns & limits
  • Long-term safety data for the continuous use of the specific CJC-1295/Ipamorelin combination in humans is limited.
  • The exact optimal dosing ratio and frequency for maximizing benefits while minimizing receptor desensitization remain under investigation.
  • Potential risks of prolonged elevated IGF-1 levels, including theoretical cancer risks, require further long-term study.

06Safety & regulatory context

Regulatory statusBoth CJC-1295 and Ipamorelin are experimental research chemicals and are not FDA-approved for human use. They are often prescribed off-label by compounding pharmacies for anti-aging and wellness. Potential side effects include injection site reactions, water retention, increased hunger, flushing, and mild headaches. Due to their effects on growth hormone, they are banned by the World Anti-Doping Agency (WADA) for use in competitive sports.

07Compared with Tesamorelin

CJC-1295/Ipamorelin Blend vs. Tesamorelin
Key difference
Tesamorelin is an FDA-approved GHRH analog specifically for HIV-associated lipodystrophy, whereas the CJC/Ipamorelin blend combines a GHRH with a GHRP for broader, synergistic GH release.
When researchers discuss each
Tesamorelin is discussed in the context of targeted visceral fat reduction with clinical approval, while the CJC/Ipamorelin blend is discussed in anti-aging and performance research for overall body composition and recovery.

08Glossary

GHRH (Growth Hormone-Releasing Hormone)
A hormone produced in the hypothalamus that stimulates the pituitary gland to release growth hormone.
GHRP (Growth Hormone Releasing Peptide)
A class of synthetic peptides that mimic the hunger hormone ghrelin to stimulate growth hormone release.
Synergistic
An interaction where the combined effect of two substances is greater than the sum of their separate effects.
Pulsatile Release
The secretion of hormones in bursts or pulses rather than a continuous, steady stream, which is how growth hormone is naturally released.

09Knowledge check

Q1Why are CJC-1295 and Ipamorelin often combined in research?
Q2What is a key advantage of Ipamorelin compared to other growth hormone secretagogues?
Q3Which limitation about the CJC-1295/Ipamorelin combination is explicitly stated in the dossier?
Q4According to the dossier comparison, how is Tesamorelin discussed differently from the CJC-1295/Ipamorelin blend?
Q5Which statement best reflects the safety and regulatory context for CJC-1295 and Ipamorelin as described in the dossier?

10Sources

More in Growth Hormone

See all

Sermorelin

Growth Hormone
FDA-approved context

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to naturally produce and release human growth hormone (hGH), making it a subject of research for age-related growth hormone decline, body composition, and vitality.

200-500 mcg/day

Tesamorelin

Growth Hormone
FDA-approved context

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete growth hormone. It is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy and is being researched for potential cognitive benefits.

2 mg/day

Hexarelin

Growth Hormone
Human clinical

Hexarelin is a potent, synthetic hexapeptide and growth hormone secretagogue (GHS) that stimulates the release of growth hormone. Research indicates it is one of the strongest GH-releasing peptides available, offering potential benefits for muscle growth, fat loss, and cardiovascular health without significantly increasing appetite.

100-200 mcg per dose
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.